Literature DB >> 5318575

Antibiotic therapy of staphylococcal infections.

G H Hawks.   

Abstract

The antibiotic treatment of staphylococcal infections remains a problem. Isolation of the organism and sensitivity testing are necessary in the choice of antibiotic. Penicillin G is the most effective penicillin against non-penicillinase-producing staphy-lococci; for the penicillinase producers there is very little to choose between the semisynthetic penicillins, methicillin, cloxacillin, nafcillin and oxacillin. For patients who are hypersensitive to penicillin, the bacteriostatic drugs (erythromycin, novobiocin, tetracycline, chloramphenicol, oleandomycin) are useful for mild infections, while for more severe illness the bactericidal drugs (vancomycin, ristocetin, kanamycin, bacitracin, neomycin) have been used successfully. Acute staphylococcal enterocolitis is probably best treated by a semisynthetic penicillin. Other antibiotics which have been found useful, with clinical trials, for staphylococcal infections are cephalosporin, fucidin, cephaloridine and lincomycin. The latter drug has been reported of value in the treatment of osteomyelitis. There is little justification for the prophylactic use of antibiotics to prevent staphylococcal infection. Surgical drainage is still an important adjunct in the treatment of many staphylococcal infections.

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 5318575      PMCID: PMC1928945     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  3 in total

1.  [Present importance of staphylogenic infection in dermatology].

Authors:  H Bergmann; I Müller
Journal:  Arch Klin Exp Dermatol       Date:  1966

2.  Bacterial endocarditis occurring after open-heart surgery.

Authors:  R S Fraser; R E Rossall; J Dvorkin
Journal:  Can Med Assoc J       Date:  1967-06-17       Impact factor: 8.262

3.  A long-distance rRNA base pair impacts the ability of macrolide antibiotics to kill bacteria.

Authors:  Maxim S Svetlov; Sophie Cohen; Nada Alsuhebany; Nora Vázquez-Laslop; Alexander S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-13       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.